Cargando…

The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial

Rationale: In the IMPACT (Informing the Pathway of Chronic Obstructive Pulmonary Disease Treatment) trial, fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) significantly reduced exacerbations compared with FF/VI or UMEC/VI in patients with symptomatic chronic obstructive pulmonary diseas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, MeiLan K., Criner, Gerard J., Dransfield, Mark T., Halpin, David M. G., Jones, C. Elaine, Kilbride, Sally, Lange, Peter, Lettis, Sally, Lipson, David A., Lomas, David A., Martin, Neil, Wise, Robert A., Singh, Dave, Martinez, Fernando J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605201/ https://www.ncbi.nlm.nih.gov/pubmed/32584168 http://dx.doi.org/10.1164/rccm.201912-2478OC

Ejemplares similares

Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT
por: Dransfield, Mark T., et al.
Publicado: (2021)

Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study
por: Tabberer, Maggie, et al.
Publicado: (2020)

One More Time: The Impact of Inhaled Corticosteroid Withdrawal on IMPACT
por: Han, MeiLan K., et al.
Publicado: (2020)

The effect of exacerbation history on outcomes in the IMPACT trial
por: Halpin, David M.G., et al.
Publicado: (2020)

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
por: Day, Nicola C., et al.
Publicado: (2020)

Reply to Wang and Lai: The Role of Eosinophils during the Withdrawal of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease
por: Han, MeiLan K., et al.
Publicado: (2021)

InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations
por: Singh, Dave, et al.
Publicado: (2021)

Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis
por: Han, MeiLan K., et al.
Publicado: (2021)

Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids
por: Siddiqui, Salman H, et al.
Publicado: (2018)

Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease
por: Lipson, David A., et al.
Publicado: (2020)

Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses
por: Halpin, David M.G., et al.
Publicado: (2018)

Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial
por: Halpin, David M. G., et al.
Publicado: (2020)

Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial
por: Thompson, Philip J., et al.
Publicado: (2022)

Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial
por: Ismaila, Afisi S, et al.
Publicado: (2019)

Effect of Inhaled Corticosteroid Withdrawal on Chronic Obstructive Pulmonary Disease Exacerbations in Patients Taking Triple Therapy at Baseline
por: Ferguson, Gary T, et al.
Publicado: (2020)

Effect of inhaled corticosteroids on blood eosinophil count in steroid-naïve patients with COPD
por: Kreindler, James L, et al.
Publicado: (2016)

Inhaled corticosteroids and COVID-19-related mortality: confounding or clarifying?
por: Singh, Dave, et al.
Publicado: (2020)

Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD
por: Pavord, Ian D, et al.
Publicado: (2016)

Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective
por: Halpin, David M.G., et al.
Publicado: (2020)

Time‐Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT Trial
por: Dransfield, Mark T., et al.
Publicado: (2022)

Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms
por: Avdeev, Sergey, et al.
Publicado: (2019)

The sputum transcriptome better predicts COPD exacerbations after the withdrawal of inhaled corticosteroids than sputum eosinophils
por: Ditz, Benedikt, et al.
Publicado: (2021)

Appropriate use of inhaled corticosteroids in COPD: the candidates for safe withdrawal
por: Yawn, Barbara P, et al.
Publicado: (2016)

Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial
por: Gabrio, Andrea, et al.
Publicado: (2022)

Inhaled corticosteroid withdrawal may improve outcomes in elderly patients with COPD exacerbation: a nationwide database study
por: Jo, Taisuke, et al.
Publicado: (2020)

Overuse of inhaled corticosteroids in COPD: five questions for withdrawal in daily practice
por: Cataldo, Didier, et al.
Publicado: (2018)

Pragmatic trial on inhaled corticosteroid withdrawal in patients with COPD in general practice
por: van den Bemt, Lisette, et al.
Publicado: (2020)

Withdrawal of Inhaled Corticosteroids in Patients with COPD – A Prospective Observational Study
por: Nielsen, Anne Orholm, et al.
Publicado: (2021)

Inhaled Corticosteroids
por: Barnes, Peter J.
Publicado: (2010)

Non-adherence to inhaled corticosteroids and the risk of asthma exacerbations in children
por: Vasbinder, Erwin C, et al.
Publicado: (2016)

Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review
por: Dyer, Matthew J, et al.
Publicado: (2006)

“Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD
por: Vogelmeier, Claus, et al.
Publicado: (2017)

Inhaled Corticosteroid Withdrawal in Chronic Obstructive Pulmonary Disease: Can IMPACT Help?
por: Suissa, Samy
Publicado: (2020)

The Role of Eosinophils during the Withdrawal of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease
por: Wang, Cheng-Yi, et al.
Publicado: (2021)

A descriptive cohort study of withdrawal from inhaled corticosteroids in COPD patients
por: Patel, Smit, et al.
Publicado: (2022)

Blood eosinophilia, use of inhaled corticosteroids, and risk of COPD exacerbations and mortality
por: Oshagbemi, Olorunfemi A., et al.
Publicado: (2018)

Addition of Montelukast to Low-Dose Inhaled Corticosteroid Leads to Fewer Exacerbations in Older Patients Than Medium-Dose Inhaled Corticosteroid Monotherapy
por: Ye, Young-Min, et al.
Publicado: (2015)

Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial
por: Choudhury, Aklak B, et al.
Publicado: (2007)

The IMPACT Study – Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population
por: Kato, Motokazu, et al.
Publicado: (2019)

COVID-19, Asthma, and Inhaled Corticosteroids: Another Beneficial Effect of Inhaled Corticosteroids?
por: Maes, Tania, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5fds9umhu8eo1c4org9l948s0f